Title

Corn Occupational Rhinitis SCIT Efficacy Study
Corn Based Occupational Rhinitis; SCIT Efficacy Study
  • Phase

    N/A
  • Study Type

    Interventional
  • Status

    Unknown status
  • Study Participants

    40
Patients demonstrated allergic to corn pollen and timothy grass pollen (by allergy testing) who have undergone 1 to 2 years of subcutaneous allergen immunotherapy (SCIT) containing timothy grass extract with moderate symptomology (as documented via rhinitis symptom score surveys) will constitute the treatment group. Those who previously chose not to undergo SCIT who have documented symptomology and are skin test positive to corn pollen will constitute the control group. Prospective symptom score analyses and retrospective quality of life assessments (RQLQ) will be the primary and secondary efficacy outcome measures.
Statistical assessment suggests enrollment of 20 patients into the treatment group (defined above) and an additional 20 into the control group. Patients will be matched for the level of symptomology (based on symptom score surveys) and residing/working on corn-crop farms. The premise for this study is the cross-reactivity of putative immunogenic sites between timothy grass pollen and corn pollen. based on consensus genetic sequences. Thus, the hypothesis is the use of Timothy grass extract containing immunotherapy would diminish symptomology to corn-based occupational rhinitis. Enrolled patients will have signed IRB approved consent forms and have undergone SCIT for 1 to 2 plus years (treatment group) or not undergone SCIT therapy for the same time period (control group). Potential contribution to symptom scores from other sources (e.g. Ragweed) will be analyzed by assessment of local pollen counts.Efficacy assessment will compare prospective symptom score results and retrospective quality of life survey scores between the treatment and control group responses.
Study Started
Aug 31
2016
Primary Completion
Nov 30
2016
Study Completion
Dec 31
2018
Anticipated
Last Update
May 02
2018

Biological subcutaneous allergen immunotherapy (SCIT)

20 patients who (prior to study enrollment and initiation) completed more than 1 year of timothy grass SCIT vs. 20 control patients who underwent corn pollen exposure for for greater than one year during the same prestudy time interval. Efficacy will be assessed by analyses of symptom score surveys and quality of life surveys.

Biological SCIT

Treatment group consists of patients who completed > 1 year of SCIT while control group patients did not undergo SCIT

Treatment Group Experimental

the treatment -patients underwent SCIT and antihistamine/nasal steroid/use.

Control Group No Intervention

Control patient group only used antihistamines/nasal steroids but no SCIT

Criteria

Inclusion Criteria for treatment group:

Completing more than 1 year of timothy grass SCIT
Residing/working on/near a corn farm
Having an initial symptom score value of > 8 (out of a possible 21).

Inclusion Criteria for control group:

Never treated with SCIT.
Residing/working on/near a corn farm
Having an initial symptom score value of > 8 (out of a possible 21).

All accepted enrolled patients are healthy volunteers.

Exclusion Criteria:

Negative allergy test to corn pollen,
Not residing on/near farm growing corn,
An initial symptom score of < 9.
No Results Posted